New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSpermidine vs Orforglipron

Spermidine vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & LongevityCognitive Enhancement
Spermidine
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
Spermidine is a naturally occurring polyamine found in all living cells, with exceptionally high concentrations in wheat germ, aged cheese, and human sperm. It is the most studied autophagy-inducing dietary compound, shown to extend lifespan across multiple species and reduce cardiovascular and cognitive aging.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
~30–60 minutes, but gut bacteria produce it continuously; supplementation raises tissue levels over weeks
~12 hours (once-daily oral dosing)
Admin Route
Oral
Oral
Research
Typical Dose
1–5 mg
12 mg → 24 mg → 36 mg → 45 mg
Frequency
Once daily
Once daily
Key Benefits
  • Induces autophagy — cellular self-cleaning
  • Extends lifespan in yeast, flies, worms, and mice
  • Reduces cardiovascular aging and arterial stiffness
  • Reduces all-cause mortality (human epidemiological data)
  • Neuroprotective: reduces amyloid and tau pathology
  • Promotes hair growth (anagen phase activation)
  • Reduces age-related immune decline
  • Improves memory in aging models
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Generally very well tolerated
  • Rare: mild GI discomfort at high doses
  • May temporarily reduce some gut bacteria species
  • Rare: headache at initiation
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With